Lilly started the world’s first study of antibody treatment among humans. LY-CoV555, a name for the investigative medicine, is a result of a collaborative effort with AbCellera to develop antibodies to attack the virus SARS-CoV-2 which causes COVID-19. Lilly developed the antivirus after AbCellera, and the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID) successfully discovered the virus in a patient about three months back. Upon successful completion of phase 1 trials, Lilly plans to test the vaccine among the more vulnerable non hospitalised sections of the population. The global healthcare giant has also starting large scale manufacturing of the drug to make available the vaccine in the shortest possible time as and when it gets approved. LY-CoV555 is the world’s first vaccine which directly attacks the virus setting it up another level compared to the existing vaccine in the trial for the novel Coronavirus.